Continuous insulin infusions trump multiple daily injections in type 1/2 diabetes
20 Jan 2020
byTristan Manalac
Continuous subcutaneous insulin infusion (CSII) appears to be superior to multiple daily injections (MDI) for the management of type 1 or 2 diabetes, leading to lower rates of cardiovascular events and better glycaemic control, according to a new study.
